A Reversal for ProMetic Life Sciences Inc. Is Not Near. The Stock Declines Again

 A Reversal for ProMetic Life Sciences Inc. Is Not Near. The Stock Declines Again

The stock of ProMetic Life Sciences Inc. (TSE:PLI) is a huge mover today! About 572,462 shares traded hands. ProMetic Life Sciences Inc. (TSE:PLI) has declined 28.65% since April 21, 2016 and is downtrending. It has underperformed by 34.06% the S&P500.
The move comes after 5 months negative chart setup for the $1.53B company. It was reported on Nov, 25 by Barchart.com. We have $2.29 PT which if reached, will make TSE:PLI worth $76.50M less.

ProMetic Life Sciences Inc. (TSE:PLI) Ratings Coverage

Out of 6 analysts covering ProMetic Life Sciences Inc. (TSE:PLI), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. ProMetic Life Sciences Inc. has been the topic of 24 analyst reports since August 10, 2015 according to StockzIntelligence Inc. The stock of ProMetic Life Sciences Inc. (TSE:PLI) has “Outperform” rating given on Friday, October 21 by RBC Capital Markets. The firm earned “Outperform” rating on Tuesday, December 15 by RBC Capital Markets. The stock has “Outperform” rating given by Scotia Capital on Thursday, August 11. RBC Capital Markets maintained the stock with “Outperform” rating in Tuesday, November 22 report. The stock of ProMetic Life Sciences Inc. (TSE:PLI) earned “Outperform” rating by RBC Capital Markets on Monday, October 5. As per Thursday, October 27, the company rating was maintained by TD Securities. On Tuesday, December 8 the stock rating was maintained by RBC Capital Markets with “Outperform”. The stock of ProMetic Life Sciences Inc. (TSE:PLI) earned “Outperform” rating by RBC Capital Markets on Thursday, August 25. The stock of ProMetic Life Sciences Inc. (TSE:PLI) has “Outperform” rating given on Monday, August 10 by Scotia Capital. The firm earned “Outperform” rating on Thursday, October 27 by RBC Capital Markets.

More news for ProMetic Life Sciences Inc. (TSE:PLI) were recently published by: Marketwatch.com, which released: “Thomvest Asset Management Inc. reports Prometic Life Sciences Inc. share …” on March 11, 2016. Finance.Yahoo.com‘s article titled: “Telesta Therapeutics Inc. announces closing of arrangement with Prometic Life …” and published on October 31, 2016 is yet another important article.

ProMetic Life Sciences Inc. is a Canada biopharmaceutical company. The company has a market cap of $1.53 billion. The Firm has two divisions: Small Molecule Therapeutics and Protein Technology. It currently has negative earnings. The Firm offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment